[1] Strauss KA,Morton DH.Branched-chain ketoacyl dehydrogenase deficiency:maple syrup disease[J].Curr Treat Options Neurol,2003,5(4):329-341.
[2] 惠秦,谷为岳,侯新琳,等,新生儿枫糖尿症1例[J].中国循证儿科杂志,2014,9(1):64-67.
[3] Strauss KA,Bridget W,Donna R,et al.Classical maple syrup urine disease and brain development:Principles of management and formula design[J].Mol Genet Metab,2010,99(4):333-345.
[4] Oyarzabal A,Martinez-Pardo M,Merinero B,et al.A Novel regulatorydefect in the branched-chain alpha-ketoacid dehydrogenasecomplex due to a mutation in the PPM1K gene causes a mild variantphenotype of maple syrup urine disease[J].Hum Mutat,2012,34(2):355-362.
[5] Gupta D,Bijarnia-Mahay S,Saxena R,et al.Identification of mutations,genotype-phenotype correlation and prenatal diagnosis of maple syrup urine disease in Indian patients[J].Eur J Med Genet,2015,58(9):471-478.
[6] Nellis MM,Danner DJ.Gene preference in maple syrup urine disease[J].Am J Hum Genet,2001,68(1):232-237.
[7] Zinnanti WJ,Lazoric J,Griffin K,et al.Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease[J].Brain,2009,132(pt4):903-918.
[8] Emilieu RM,Gregory JM,Scott CB,et al.Biochemical correlates off neuropsychiatric illness in maple syrup urine disease[J].J Clin Invest,2013,123(4):1809-1820.
[9] Yang N,Han LS,Ye J,et al.Clinical characteristics and analysis of mass spectrometric data in 33 patients with maple syrup urine disease[J].Zhonghua Yi Xue Za Zhi,2012,92(40):2839-2842.
[10] Couce ML,Ramos F,Bueno MA,et al.Evolution of maple syrup urine disease in patients diagnosed by newborn screening versus late diagnosis[J].Eur J Paediatr Neurol,2015,19(6):652-659.
[11] Schadewaldt P,Bodner-Leidecker A,Hammen HW,et al.Significance of L-alloisoleucine in plasma for diagnosis of maple syrup urine disease[J].Clin Chem,1999,45(10):1734-1740.
[12] Kevin AS,Bridget W,Donna R,et al.Classical maple syrup urine disease and brain develogment:Principles of management and formula design[J].Mol Genet Metab,2010,99(4):333-345.
[13] Homanics GE,Skvorak K,Ferguson C,et al.Production and characterization of murine models of classic and intermediate maple syrup urine disease[J].BMC Med Genet,2006,7(2):33.
[14] Indiran V,Gunaseelan RE.Neuroradiological findings in maple syrup urine disease[J].J Pediatr Neurosci,2013,8(1):31-33.
[15] Atwal PS,Macmurdo C,Grimm PC.Haemodialysis is an effective treatment in acute metabolic decompensation of maple syrup urine disease[J].Mol Genet Metab Rep,2015,4(5):46-48.
[16] William JZ,Jelena L,Kathleen G,et al.Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease[J].Brain,2009,132(4):903-918.
[17] Chin HL,Aw MM,Quak SH,et al.Two consecutive partial liver transplants in a patient with classic maple syrup urine disease[J].Mol Genet Metab Rep,2015,4(1):49-52.
[18] Mazariegos GV,Morton DH,Sindhi R.Liver transplantation for classical maple syrup urine disease:long-term follow-up in 37 patients and comparative united network for organ sharing experience[J].J Pediatr,2012,160(1):116-121.
[19] Kristen JS,Kenneth D,Fabio M,et al.Placental stem cell correction of murine intermediate maple syrup urine disease[J].Hepatology,2013,57(3):1017-1023.
[20] Homanics GE,Skvorak K,Ferguson C,et al.Phenylbutyrate therapy for maple syrup urine disease[J].Hum Mol Genet,2011,20(4):631-640.
[21] Yang N,Han L,Gu X,et al.Analysis of gene mutations in Chinese patients with maple syrup urine disease[J].Mol Genet Metab,2012,106(4):412-418. |